- Report
- February 2025
- 90 Pages
Global
From €5255EUR$5,950USD£4,489GBP
- Report
- May 2025
- 189 Pages
Global
From €3131EUR$3,545USD£2,675GBP
€3479EUR$3,939USD£2,972GBP
- Report
- February 2025
- 240 Pages
Global
From €2376EUR$2,690USD£2,029GBP
- Report
- April 2025
Global
From €4328EUR$4,900USD£3,697GBP
- Report
- February 2025
- 200 Pages
Global
From €3966EUR$4,490USD£3,387GBP
- Report
- June 2025
- 483 Pages
Global
From €5167EUR$5,850USD£4,413GBP
- Report
- June 2025
- 93 Pages
Global
From €5167EUR$5,850USD£4,413GBP
- Report
- January 2025
- 135 Pages
Global
From €2649EUR$2,999USD£2,263GBP
- Report
- June 2025
- 400 Pages
Global
From €4371EUR$4,949USD£3,734GBP
- Report
- October 2024
- 250 Pages
Global
From €4371EUR$4,949USD£3,734GBP
- Drug Pipelines
- August 2024
- 150 Pages
Global
From €2463EUR$2,789USD£2,104GBP
- Report
- January 2025
- 182 Pages
Global
From €3378EUR$3,825USD£2,886GBP
€3974EUR$4,500USD£3,395GBP
- Report
- May 2024
- 132 Pages
Global
From €5740EUR$6,499USD£4,903GBP
- Report
- January 2024
- 200 Pages
Global
From €3665EUR$4,150USD£3,131GBP
- Report
- January 2024
- 395 Pages
Global
From €6624EUR$7,500USD£5,658GBP

Perampanel is a drug used to treat seizures associated with epilepsy. It is a non-competitive antagonist of the AMPA receptor, which is a type of glutamate receptor found in the central nervous system. Perampanel is the first and only drug of its kind to be approved by the US Food and Drug Administration (FDA). It is available in tablet form and is taken orally.
Perampanel is used as an adjunctive therapy for partial-onset seizures in adults and adolescents aged 12 years and older. It is also used as an adjunctive therapy for primary generalized tonic-clonic seizures in adults and adolescents aged 12 years and older.
The market for perampanel is growing as more people are being diagnosed with epilepsy and other seizure disorders. It is an important drug in the treatment of these conditions and is becoming increasingly popular due to its effectiveness and safety profile.
Companies in the perampanel market include Eisai Co., Ltd., UCB Pharma, and Sunovion Pharmaceuticals. Show Less Read more